All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

clonidine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
alpha-2 adrenoreceptor agonists	704	4205-90-7

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: clonidine clonidine hydrochloride clonidine HCl	An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION. Molecular weight: 230.09 Formula: C9H9Cl2N3 CLOGP: 1.73 LIPINSKI: 0 HAC: 3 HDO: 2 TPSA: 36.42 ALOGS: -2.68 ROTB: 1 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
0.45	mg	O
0.45	mg	P
0.10	mg	O

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.17 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Hosey CM, Chan R, Benet LZ
EoM (Fraction excreted unchanged in urine)	62 %	Hosey CM, Chan R, Benet LZ
BA (Bioavailability)	95 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	3.30 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	4 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.56 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	7.60 hours	Lombardo F, Berellini G, Obach RS
S (Water solubility)	50 mg/mL	Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2A,ACVR2B,ALK,AXL,BRAF,CAMK2B,CAMK2D,CDK5,CDK9,CSF1R,DDR1,DYRK1B,EPHB4,ERBB2,FLT3,FYN,GRK2,ITK,JAK1,JAK2,KIT,LYN,MAP3K1,MAP3K21,MAP3K7,MAP4K1,MAPK7,MAPK9,MARK4,MTOR,NTRK2,PDK2,PDK4,PIK3CB,PIK3CD,PIM2,PRKCD,PRKDC,SGK1,SIK2,SIK3,STK33,TEK,TTK	44
kinase-selectivity-class	ACVR2B,AXL,BRAF,DDR1,EPHB4,ERBB2,GRK2,MAPK7,PDK4,SIK2,SIK3	11
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

Date	Agency	Company	Orphan
Sept. 3, 1974	FDA	BOEHRINGER INGELHEIM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Food allergy	701.87	9.62	401	97402	25077	90505567
Temperature regulation disorder	645.19	9.62	315	97488	14264	90516380
Immunodeficiency	537.13	9.62	414	97389	42820	90487824
Completed suicide	482.62	9.62	684	97119	144374	90386270
Hyperhidrosis	418.76	9.62	619	97184	135686	90394958
Upper respiratory tract infection	374.53	9.62	569	97234	127749	90402895
Rash erythematous	359.58	9.62	396	97407	64708	90465936
Overdose	342.43	9.62	612	97191	157097	90373547
Hypertension	310.64	9.62	1141	96662	456391	90074253
Coeliac disease	282.81	9.62	292	97511	44318	90486326
Fluid retention	268.87	9.62	399	97404	87692	90442952
Prescribed overdose	258.42	9.62	414	97389	97211	90433433
Intentional product misuse	256.63	9.62	394	97409	89210	90441434
Foetal death	247.64	9.62	194	97609	20529	90510115
Bradycardia	180.05	9.62	324	97479	83523	90447121
Drug withdrawal syndrome	157.28	9.62	174	97629	28549	90502095
Hypertensive crisis	155.48	9.62	139	97664	17645	90512999
Cardiac failure congestive	144.33	9.62	325	97478	98369	90432275
Asthma	135.55	9.62	569	97234	241591	90289053
Synovitis	131.82	9.62	98	97705	329654	90200990
Systemic lupus erythematosus	128.14	9.62	121	97682	361775	90168869
Mental status changes	123.01	9.62	193	97610	44486	90486158
Therapeutic product effect decreased	116.84	9.62	78	97725	277493	90253151
Neovascularisation	115.80	9.62	49	97754	1581	90529063
Suspected suicide	113.07	9.62	89	97714	9479	90521165
Lower respiratory tract infection	108.82	9.62	68	97735	250591	90280053
Pemphigus	106.91	9.62	117	97686	326747	90203897
Paradoxical drug reaction	105.67	9.62	70	97733	5696	90524948
Maternal exposure during pregnancy	103.94	9.62	142	97661	359921	90170723
Gastrointestinal disorder	102.92	9.62	76	97727	256611	90274033
Constipation	102.33	9.62	583	97220	279812	90250832
Arthropathy	99.25	9.62	151	97652	366091	90164553
Application site rash	98.46	9.62	51	97752	2618	90528026
Anti-neutrophil cytoplasmic antibody positive vasculitis	97.11	9.62	58	97745	3935	90526709
Application site pruritus	96.35	9.62	59	97744	4188	90526456
Bursitis	96.34	9.62	337	97466	131317	90399327
Blood pressure inadequately controlled	96.15	9.62	68	97735	6156	90524488
Body tinea	93.77	9.62	46	97757	2102	90528542
Nephrogenic systemic fibrosis	90.48	9.62	56	97747	4052	90526592
Withdrawal syndrome	84.99	9.62	113	97690	22411	90508233
Product adhesion issue	83.68	9.62	58	97745	5084	90525560
Alopecia	83.13	9.62	266	97537	494805	90035839
C-reactive protein abnormal	82.99	9.62	18	97785	127411	90403233
Neutropenia	82.15	9.62	73	97730	224831	90305813
Hypotension	81.72	9.62	616	97187	324781	90205863
Glossodynia	81.21	9.62	139	97664	321640	90209004
Psoriasis	80.13	9.62	344	97459	147410	90383234
Ill-defined disorder	77.71	9.62	52	97751	184839	90345805
Toxicity to various agents	77.46	9.62	554	97249	287292	90243352
Inhibitory drug interaction	77.07	9.62	46	97757	3117	90527527
Hand deformity	75.72	9.62	127	97676	296235	90234409
Blood pressure increased	74.50	9.62	414	97389	196803	90333841
Swelling	73.98	9.62	220	97583	418838	90111806
Sinus bradycardia	73.31	9.62	91	97712	16861	90513783
Poisoning	72.84	9.62	86	97717	15131	90515513
Arthralgia	72.67	9.62	517	97286	778005	89752639
Anti-cyclic citrullinated peptide antibody positive	72.56	9.62	89	97714	236344	90294300
Distributive shock	71.19	9.62	45	97758	3379	90527265
Withdrawal hypertension	69.46	9.62	19	97784	150	90530494
Hypertensive encephalopathy	68.34	9.62	27	97776	728	90529916
Infection susceptibility increased	67.95	9.62	46	97757	3880	90526764
Application site erythema	67.11	9.62	51	97752	5157	90525487
Pericarditis	66.06	9.62	119	97684	270032	90260612
Cerebrovascular accident	64.97	9.62	285	97518	123248	90407396
Joint dislocation	64.23	9.62	146	97657	44436	90486208
Facet joint syndrome	63.86	9.62	14	97789	98375	90432269
Exposure during pregnancy	63.04	9.62	457	97346	237953	90292691
Back pain	61.72	9.62	567	97236	316608	90214036
Febrile neutropenia	60.75	9.62	49	97754	158300	90372344
Abdominal discomfort	57.62	9.62	292	97511	477036	90053608
Accidental exposure to product by child	56.56	9.62	28	97775	1305	90529339
Malignant neoplasm progression	55.29	9.62	23	97780	106847	90423797
Erythema	55.27	9.62	430	97373	228816	90301828
Seronegative arthritis	53.31	9.62	81	97722	18153	90512491
Inflammation	52.93	9.62	69	97734	178523	90352121
Wound	52.76	9.62	160	97643	302820	90227824
Hepatic enzyme increased	52.61	9.62	608	97195	360128	90170516
Glucose tolerance impaired	51.90	9.62	53	97750	7932	90522712
Application site irritation	51.67	9.62	30	97773	1931	90528713
Decreased immune responsiveness	51.38	9.62	55	97748	8693	90521951
Sedation	50.72	9.62	140	97663	48031	90482613
Product tampering	50.63	9.62	19	97784	444	90530200
Lip dry	50.21	9.62	23	97780	100932	90429712
Duodenal ulcer perforation	48.45	9.62	104	97699	221184	90309460
Cardio-respiratory arrest	48.23	9.62	164	97639	62976	90467668
Intentional product use issue	46.60	9.62	103	97700	216789	90313855
Somnolence	46.48	9.62	385	97418	208699	90321945
Discomfort	46.25	9.62	147	97656	274188	90256456
Adulterated product	46.13	9.62	17	97786	377	90530267
Myocardial infarction	45.84	9.62	231	97572	105741	90424903
Liver disorder	44.70	9.62	39	97764	121230	90409414
Headache	44.58	9.62	1232	96571	861514	89669130
Night sweats	44.41	9.62	44	97759	128722	90401922
Unresponsive to stimuli	44.38	9.62	115	97688	38006	90492638
Hypothermia	43.86	9.62	68	97735	15507	90515137
Hypertensive emergency	43.27	9.62	28	97775	2189	90528455
Hypersensitivity	43.26	9.62	710	97093	453967	90076677
Acute motor-sensory axonal neuropathy	43.24	9.62	16	97787	359	90530285
Cardiac arrest	42.79	9.62	225	97578	104710	90425934
Intestinal angioedema	42.61	9.62	20	97783	828	90529816
Malignant catatonia	42.35	9.62	14	97789	222	90530422
Peripheral venous disease	41.92	9.62	19	97784	83902	90446742
Respiratory arrest	41.39	9.62	103	97700	33208	90497436
Thrombocytopenia	41.00	9.62	374	97429	208351	90322293
Anuria	40.76	9.62	64	97739	14754	90515890
Condition aggravated	39.71	9.62	431	97372	595114	89935530
Walking aid user	39.19	9.62	105	97698	35401	90495243
Poor quality sleep	39.11	9.62	84	97719	24609	90506035
Malignant hypertension	38.69	9.62	21	97782	1186	90529458
Peritonitis bacterial	38.58	9.62	37	97766	5134	90525510
Disease progression	38.25	9.62	69	97734	156546	90374098
Musculoskeletal pain	37.88	9.62	80	97723	171171	90359473
Interstitial lung disease	37.08	9.62	18	97785	76387	90454257
Rheumatoid arthritis	37.01	9.62	573	97230	362041	90168603
Agitation	36.95	9.62	157	97646	66941	90463703
Implant site extravasation	36.89	9.62	16	97787	549	90530095
Anti-cyclic citrullinated peptide antibody	36.85	9.62	87	97716	27134	90503510
Claustrophobia	36.83	9.62	21	97782	1306	90529338
Malaise	36.74	9.62	430	97373	585556	89945088
Live birth	36.37	9.62	20	97783	79087	90451557
Extrapyramidal disorder	36.25	9.62	64	97739	16239	90514405
Psoriatic arthropathy	35.98	9.62	126	97677	228209	90302435
Aggression	35.85	9.62	85	97718	26583	90504061
Lung disorder	35.74	9.62	67	97736	149816	90380828
Skin induration	35.68	9.62	29	97774	3233	90527411
Nodal rhythm	35.58	9.62	23	97780	1795	90528849
Spinal fusion surgery	35.11	9.62	54	97749	12229	90518415
Systolic dysfunction	34.61	9.62	23	97780	1881	90528763
Abdominal pain upper	34.40	9.62	214	97589	332460	90198184
Nasopharyngitis	33.79	9.62	279	97524	406825	90123819
Chronic kidney disease	33.73	9.62	125	97678	50066	90480578
Impaired quality of life	33.56	9.62	76	97727	23068	90507576
Tachycardia	32.74	9.62	286	97517	157387	90373257
Abortion spontaneous	32.53	9.62	9	97794	54047	90476597
White blood cell count decreased	32.21	9.62	84	97719	167025	90363619
Psychomotor hyperactivity	32.05	9.62	53	97750	12760	90517884
Blepharospasm	31.96	9.62	10	97793	55435	90475209
Hyperlipidaemia	31.85	9.62	74	97729	22842	90507802
Rheumatoid factor positive	31.79	9.62	88	97715	171562	90359082
Folliculitis	31.37	9.62	114	97689	204239	90326405
Pulse abnormal	30.82	9.62	26	97777	3053	90527591
Spondylitis	30.68	9.62	55	97748	14123	90516521
Acute myocardial infarction	30.59	9.62	95	97708	34795	90495849
Dissociation	30.58	9.62	37	97766	6678	90523966
Product substitution issue	30.54	9.62	63	97740	17945	90512699
Coronary artery disease	29.90	9.62	92	97711	33531	90497113
Left ventricular hypertrophy	29.86	9.62	35	97768	6109	90524535
Respiratory depression	29.42	9.62	57	97746	15518	90515126
Taste disorder	29.11	9.62	15	97788	61531	90469113
Joint stiffness	28.88	9.62	163	97640	77879	90452765
Muscle injury	28.83	9.62	96	97707	176558	90354086
Diarrhoea	28.74	9.62	783	97020	938407	89592237
Blister	28.49	9.62	160	97643	254838	90275806
Pathergy reaction	28.22	9.62	8	97795	73	90530571
Respiratory moniliasis	27.87	9.62	10	97793	205	90530439
Neutrophil count decreased	27.59	9.62	22	97781	71510	90459134
Skin hypertrophy	27.25	9.62	26	97777	3584	90527060
Medical device site pain	27	9.62	10	97793	225	90530419
Delirium	26.95	9.62	199	97604	104160	90426484
Depressed level of consciousness	26.92	9.62	152	97651	72632	90458012
Lethargy	26.85	9.62	137	97666	63002	90467642
Schizencephaly	26.68	9.62	11	97792	332	90530312
Anaesthesia	26.62	9.62	12	97791	452	90530192
Purpura	26.61	9.62	53	97750	14725	90515919
Cerebral haemorrhage foetal	26.53	9.62	11	97792	337	90530307
Sleep disorder due to general medical condition, insomnia type	26.11	9.62	63	97740	128631	90402013
Mucosal erosion	25.85	9.62	19	97784	1826	90528818
Epilepsy with myoclonic-atonic seizures	25.59	9.62	8	97795	105	90530539
Basal ganglion degeneration	25.54	9.62	11	97792	371	90530273
Sinusitis	25.43	9.62	242	97561	342846	90187798
Drug intolerance	25.18	9.62	336	97467	447255	90083389
Hypertensive urgency	24.99	9.62	13	97790	673	90529971
Accidental overdose	24.80	9.62	77	97726	28196	90502448
Miosis	24.76	9.62	40	97763	9444	90521200
Retching	24.61	9.62	60	97743	19099	90511545
Retrograde amnesia	24.59	9.62	12	97791	542	90530102
Osteonecrosis of jaw	24.50	9.62	6	97797	39097	90491547
Injection site erythema	24.40	9.62	43	97760	98459	90432185
Human ehrlichiosis	24.36	9.62	9	97794	201	90530443
Nail disorder	24.29	9.62	17	97786	59050	90471594
Epilepsy	24.10	9.62	32	97771	82174	90448470
Primary hyperaldosteronism	23.52	9.62	7	97796	77	90530567
Gastrooesophageal reflux disease	23.46	9.62	96	97707	166241	90364403
Macular degeneration	23.46	9.62	6	97797	37964	90492680
Hepatitis	23.45	9.62	25	97778	70714	90459930
BRASH syndrome	23.33	9.62	18	97785	1861	90528783
Lupus-like syndrome	22.92	9.62	109	97694	48737	90481907
Sleep disorder	22.80	9.62	123	97680	197907	90332737
Retinitis	22.75	9.62	92	97711	38366	90492278
Hepatic cirrhosis	22.68	9.62	131	97672	63122	90467522
Somatic symptom disorder	22.66	9.62	23	97780	3418	90527226
Hypercholesterolaemia	22.51	9.62	186	97617	100706	90429938
Alanine aminotransferase increased	22.41	9.62	60	97743	118278	90412366
Hepatic function abnormal	22.32	9.62	11	97792	46277	90484367
COVID-19	22.25	9.62	100	97703	168743	90361901
Hypoventilation	22.21	9.62	28	97775	5268	90525376
Peripheral swelling	22.20	9.62	313	97490	412793	90117851
Musculoskeletal stiffness	22.03	9.62	209	97594	296323	90234321
Device infusion issue	21.68	9.62	20	97783	2642	90528002
Ear infection	21.53	9.62	139	97664	69636	90461008
Colitis ulcerative	21.46	9.62	20	97783	60246	90470398
Catheter site granuloma	21.34	9.62	5	97798	19	90530625
Impaired work ability	21.17	9.62	57	97746	19269	90511375
Bone density decreased	20.89	9.62	53	97750	17292	90513352
Blood aldosterone increased	20.78	9.62	8	97795	201	90530443
Onychomadesis	20.61	9.62	12	97791	45986	90484658
Genital erosion	20.46	9.62	10	97793	453	90530191
Norepinephrine increased	20.41	9.62	6	97797	63	90530581
Rheumatic fever	19.98	9.62	91	97712	153030	90377614
Rhinorrhoea	19.74	9.62	41	97762	88275	90442369
Apnoea	19.71	9.62	36	97767	9378	90521266
Dialysis	19.64	9.62	40	97763	11289	90519355
Application site papules	19.61	9.62	6	97797	73	90530571
Skin disorder	19.52	9.62	85	97718	36621	90494023
Tissue infiltration	19.52	9.62	12	97791	858	90529786
Seizure	19.49	9.62	251	97552	152378	90378266
Pregnancy	19.39	9.62	23	97780	62024	90468620
Iliac artery stenosis	19.39	9.62	6	97797	76	90530568
Brain injury	19.34	9.62	32	97771	7706	90522938
Device expulsion	19.29	9.62	10	97793	40876	90489768
Paraesthesia	19.21	9.62	175	97628	250151	90280493
Sympathomimetic effect	19.18	9.62	7	97796	151	90530493
Disability	19.17	9.62	91	97712	40654	90489990
Drug ineffective	19.12	9.62	1263	96540	1383035	89147609
Fibrous dysplasia of jaw	18.95	9.62	4	97799	8	90530636
Obesity	18.86	9.62	55	97748	105452	90425192
Intentional overdose	18.85	9.62	169	97634	93665	90436979
Drug dependence	18.84	9.62	72	97731	29255	90501389
Lupus vulgaris	18.62	9.62	97	97706	44962	90485682
Encephalomalacia	18.62	9.62	10	97793	553	90530091
Feeling of despair	18.56	9.62	20	97783	3184	90527460
Urinary incontinence	18.48	9.62	85	97718	37481	90493163
Haematochezia	18.45	9.62	30	97773	70883	90459761
Product use issue	18.33	9.62	476	97327	329443	90201201
Stomatitis	18.18	9.62	199	97604	274499	90256145
Neoplasm progression	18.03	9.62	13	97790	44473	90486171
Medical device site discharge	18.01	9.62	5	97798	42	90530602
Secondary hypertension	17.91	9.62	8	97795	295	90530349
Atrioventricular block second degree	17.82	9.62	23	97780	4429	90526215
Application site vesicles	17.68	9.62	14	97789	1503	90529141
Drug screen positive	17.60	9.62	21	97782	3736	90526908
Renin decreased	17.55	9.62	6	97797	106	90530538
Pernicious anaemia	17.17	9.62	11	97792	845	90529799
Therapeutic product effect incomplete	16.93	9.62	131	97672	193765	90336879
Normochromic normocytic anaemia	16.84	9.62	24	97779	5078	90525566
Croup infectious	16.76	9.62	10	97793	677	90529967
Neurological symptom	16.69	9.62	28	97775	6819	90523825
Gastrointestinal tract mucosal pigmentation	16.47	9.62	10	97793	699	90529945
Coma scale abnormal	16.46	9.62	25	97778	5601	90525043
Mobility decreased	16.45	9.62	182	97621	250552	90280092
Pulse absent	16.44	9.62	26	97777	6029	90524615
Myocardial ischaemia	16.42	9.62	42	97761	13772	90516872
Respiratory tract infection	16.32	9.62	24	97779	59054	90471590
Vascular stenosis	16.28	9.62	9	97794	527	90530117
X-ray abnormal	16.26	9.62	15	97788	45409	90485235
Application site discolouration	16.26	9.62	11	97792	927	90529717
Electrocardiogram PR shortened	16.20	9.62	9	97794	532	90530112
Implant site infection	16.11	9.62	12	97791	1177	90529467
Medical device site erythema	16.02	9.62	4	97799	21	90530623
Hyperreflexia	15.93	9.62	27	97776	6630	90524014
Pain	15.87	9.62	1264	96539	995077	89535567
Melaena	15.70	9.62	9	97794	34788	90495856
Cerebral ischaemia	15.68	9.62	28	97775	7168	90523476
Femur fracture	15.59	9.62	16	97787	46066	90484578
Laryngitis	15.59	9.62	101	97702	50652	90479992
Pulmonary renal syndrome	15.55	9.62	9	97794	576	90530068
Prescribed underdose	15.52	9.62	136	97667	74883	90455761
Gamma-glutamyltransferase increased	15.50	9.62	11	97792	37941	90492703
Akathisia	15.47	9.62	36	97767	11123	90519521
Application site pain	15.28	9.62	22	97781	4698	90525946
Cerebellar atrophy	15.28	9.62	10	97793	797	90529847
Rash maculo-papular	15.28	9.62	13	97790	40920	90489724
Product use in unapproved indication	15.26	9.62	263	97540	335973	90194671
Focal segmental glomerulosclerosis	15.26	9.62	14	97789	1837	90528807
Electrocardiogram QRS complex prolonged	15.26	9.62	28	97775	7320	90523324
Glomerulonephritis rapidly progressive	15.24	9.62	12	97791	1278	90529366
Rash	15.06	9.62	704	97099	795396	89735248
Onychomycosis	15.05	9.62	11	97792	37365	90493279
Page kidney	15.04	9.62	4	97799	28	90530616
Transaminases increased	14.90	9.62	11	97792	37181	90493463
Anhedonia	14.90	9.62	36	97767	11395	90519249
Frequent bowel movements	14.89	9.62	24	97779	56911	90473733
Human herpesvirus 6 infection reactivation	14.88	9.62	9	97794	625	90530019
Uterine enlargement	14.78	9.62	12	97791	1336	90529308
Pneumonia respiratory syncytial viral	14.75	9.62	12	97791	1339	90529305
Breast cancer stage II	14.75	9.62	10	97793	35324	90495320
Helicobacter infection	14.74	9.62	165	97638	226685	90303959
Exostosis	14.68	9.62	103	97700	53031	90477613
Productive cough	14.64	9.62	39	97764	77024	90453620
Cytokine release syndrome	14.50	9.62	6	97797	27967	90502677
Adverse reaction	14.42	9.62	7	97796	29705	90500939
Renal transplant failure	14.40	9.62	11	97792	1121	90529523
Feeling abnormal	14.35	9.62	257	97546	166978	90363666
Short-bowel syndrome	14.32	9.62	9	97794	669	90529975
Chest discomfort	14.29	9.62	89	97714	138276	90392368
Hyperaesthesia	14.26	9.62	34	97769	10668	90519976
Device wireless communication issue	14.24	9.62	5	97798	96	90530548
Anxiety	14.16	9.62	436	97367	309336	90221308
Sinus arrhythmia	14.02	9.62	12	97791	1437	90529207
Cardiac hypertrophy	14.01	9.62	11	97792	1167	90529477
Therapeutic drug monitoring analysis incorrectly performed	13.99	9.62	7	97796	334	90530310
Injection site abscess	13.98	9.62	12	97791	1442	90529202
Hypertrichosis	13.81	9.62	12	97791	1467	90529177
Inguinal hernia	13.77	9.62	14	97789	2084	90528560
Tachyphylaxis	13.76	9.62	7	97796	346	90530298
Exposure to allergen	13.40	9.62	8	97795	542	90530102
Basal ganglia haemorrhage	13.37	9.62	9	97794	752	90529892
Renal artery stenosis	13.34	9.62	14	97789	2163	90528481
Foot deformity	13.32	9.62	110	97693	59541	90471103
Cytomegalovirus infection	13.32	9.62	6	97797	26596	90504048
Breast cancer stage I	13.29	9.62	31	97772	9593	90521051
Hepatotoxicity	13.28	9.62	18	97785	45824	90484820
Blood pressure abnormal	13.26	9.62	49	97754	19596	90511048
Paranoia	13.08	9.62	37	97766	12871	90517773
Bone erosion	13.06	9.62	100	97703	52921	90477723
Klebsiella infection	12.96	9.62	32	97771	10265	90520379
C-reactive protein	12.93	9.62	9	97794	31358	90499286
Change in seizure presentation	12.86	9.62	8	97795	584	90530060
Bundle branch block left	12.69	9.62	27	97776	7858	90522786
Irritable bowel syndrome	12.66	9.62	153	97650	207295	90323349
Exposure via ingestion	12.64	9.62	15	97788	2652	90527992
Hepatic cytolysis	12.57	9.62	9	97794	30907	90499737
Drug abuser	12.54	9.62	15	97788	2675	90527969
Cognitive disorder	12.53	9.62	36	97767	69371	90461273
Rash pruritic	12.52	9.62	46	97757	82168	90448476
Injection site swelling	12.37	9.62	29	97774	59810	90470834
Neurological decompensation	12.35	9.62	17	97786	3484	90527160
Drug eruption	12.32	9.62	12	97791	35395	90495249
Skin fibrosis	12.12	9.62	9	97794	879	90529765
Pruritus	12.08	9.62	470	97333	541055	89989589
Intercepted medication error	12.04	9.62	9	97794	888	90529756
Basal cell carcinoma	11.98	9.62	11	97792	33378	90497266
Chloasma	11.94	9.62	5	97798	157	90530487
Loss of consciousness	11.85	9.62	215	97588	140023	90390621
Trichostasis spinulosa	11.83	9.62	3	97800	17	90530627
Acute lung injury	11.71	9.62	11	97792	1487	90529157
Creatinine renal clearance decreased	11.65	9.62	3	97800	18896	90511748
Hyperlactacidaemia	11.57	9.62	18	97785	4118	90526526
Patent ductus arteriosus	11.56	9.62	19	97784	4550	90526094
Maternal use of illicit drugs	11.54	9.62	3	97800	19	90530625
Acute myeloid leukaemia	11.41	9.62	4	97799	20636	90510008
Dermoid cyst	11.38	9.62	7	97796	501	90530143
Kidney fibrosis	11.32	9.62	13	97790	2221	90528423
Adjustment disorder with depressed mood	11.28	9.62	102	97701	56651	90473993
Aspartate aminotransferase increased	11.26	9.62	65	97738	102872	90427772
Labile blood pressure	11.20	9.62	12	97791	1898	90528746
End stage renal disease	11.18	9.62	27	97776	8544	90522100
Implant site haematoma	11.15	9.62	4	97799	82	90530562
Hypertensive heart disease	11.14	9.62	14	97789	2626	90528018
Left atrial dilatation	11.07	9.62	12	97791	1924	90528720
Infusion site infection	11.06	9.62	14	97789	2646	90527998
Mood swings	11.05	9.62	48	97755	20654	90509990
Medical device site swelling	11.04	9.62	3	97800	23	90530621
Back injury	10.97	9.62	21	97782	46601	90484043
Suicidal ideation	10.97	9.62	125	97678	73730	90456914
Pain in jaw	10.96	9.62	22	97781	47963	90482681
Neutropenic sepsis	10.94	9.62	3	97800	18127	90512517
Rectal haemorrhage	10.90	9.62	49	97754	82695	90447949
Left ventricular failure	10.85	9.62	23	97780	6677	90523967
Dislocation of vertebra	10.83	9.62	100	97703	55868	90474776
Renal failure	10.77	9.62	200	97603	130807	90399837
Urine output decreased	10.76	9.62	34	97769	12569	90518075
Emotional distress	10.68	9.62	72	97731	36590	90494054
Psychogenic seizure	10.67	9.62	12	97791	2004	90528640
Chest pain	10.66	9.62	434	97369	319211	90211433
Postoperative hypertension	10.62	9.62	3	97800	27	90530617
Hypernatraemia	10.60	9.62	28	97775	9359	90521285
Joint effusion	10.59	9.62	4	97799	19706	90510938
Skin tightness	10.47	9.62	18	97785	4470	90526174
Joint contracture	10.42	9.62	11	97792	1711	90528933
Device failure	10.39	9.62	23	97780	6874	90523770
Haemorrhage intracranial	10.38	9.62	38	97765	15124	90515520
Impaired healing	10.36	9.62	184	97619	234015	90296629
Application site haematoma	10.34	9.62	3	97800	30	90530614
Joint injury	10.32	9.62	12	97791	32652	90497992
Cytopenia	10.32	9.62	3	97800	17446	90513198
Arteriospasm coronary	10.18	9.62	19	97784	5031	90525613
Implant site hypersensitivity	10.08	9.62	3	97800	33	90530611
Hypersomnia	10.06	9.62	48	97755	21483	90509161
Alcoholism	10.02	9.62	11	97792	1789	90528855
Myalgia	10.00	9.62	131	97672	174994	90355650
Drug ineffective for unapproved indication	9.99	9.62	113	97690	66531	90464113
Electrocardiogram abnormal	9.93	9.62	29	97774	10269	90520375
Injection site pain	9.89	9.62	130	97673	173569	90357075
Cerebral atrophy	9.87	9.62	20	97783	5626	90525018
Posterior reversible encephalopathy syndrome	9.87	9.62	49	97754	22290	90508354
Blood bilirubin increased	9.86	9.62	20	97783	43450	90487194
Drug withdrawal convulsions	9.83	9.62	10	97793	1490	90529154
Bronchiectasis	9.76	9.62	6	97797	22324	90508320
Metastases to liver	9.75	9.62	10	97793	28797	90501847
Pancytopenia	9.69	9.62	83	97720	120180	90410464
Application site urticaria	9.68	9.62	5	97798	255	90530389
Peau d'orange	9.66	9.62	4	97799	122	90530522

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	338.87	11.38	483	48665	95982	42476205
Drug withdrawal syndrome	313.80	11.38	233	48915	21316	42550871
Drug dependence	194.48	11.38	202	48946	28892	42543295
Bradycardia	175.19	11.38	336	48812	85148	42487039
Aggression	174.11	11.38	234	48914	43929	42528258
Respiratory depression	169.31	11.38	154	48994	18714	42553473
Withdrawal hypertension	165.08	11.38	41	49107	194	42571993
Withdrawal syndrome	137.29	11.38	123	49025	14652	42557535
Hypertension	102.69	11.38	423	48725	166781	42405406
Hypertensive crisis	96.87	11.38	86	49062	10120	42562067
Victim of child abuse	96.32	11.38	40	49108	1149	42571038
Obesity	93.67	11.38	105	49043	16354	42555833
Epidural lipomatosis	92.47	11.38	44	49104	1756	42570431
Oppositional defiant disorder	85.19	11.38	30	49118	542	42571645
Hypotension	82.19	11.38	543	48605	257088	42315099
Decreased eye contact	80.07	11.38	28	49120	495	42571692
Suspected suicide	79.12	11.38	62	49086	6137	42566050
Agitation	76.75	11.38	204	48944	64110	42508077
Juvenile idiopathic arthritis	76.60	11.38	44	49104	2595	42569592
Choreoathetosis	75.56	11.38	33	49115	1076	42571111
Mental status changes	72.40	11.38	154	48994	41961	42530226
Dystonia	71.76	11.38	81	49067	12709	42559478
Child abuse	68.87	11.38	29	49119	863	42571324
Blood pressure inadequately controlled	65.54	11.38	41	49107	2827	42569360
Application site rash	65.43	11.38	29	49119	980	42571207
Blood prolactin increased	63.21	11.38	37	49111	2261	42569926
Cardiac failure congestive	61.75	11.38	228	48920	85374	42486813
Febrile neutropenia	61.71	11.38	74	49074	185629	42386558
Anxiety	61.30	11.38	285	48863	118275	42453912
Accidental exposure to product by child	58.93	11.38	31	49117	1536	42570651
Product prescribing error	58.84	11.38	107	49041	26005	42546182
Lethargy	58.24	11.38	151	48997	46739	42525448
Sinus bradycardia	57.42	11.38	78	49070	14775	42557412
Blood pressure increased	57.15	11.38	251	48897	101677	42470510
Homicidal ideation	56.55	11.38	37	49111	2757	42569430
Sedation	55.36	11.38	114	49034	30361	42541826
Crying	55.03	11.38	51	49097	6343	42565844
Bruxism	54.64	11.38	33	49115	2136	42570051
Serotonin syndrome	52.13	11.38	101	49047	25744	42546443
Irritability	50.83	11.38	105	49043	28023	42544164
Trismus	50.72	11.38	35	49113	2849	42569338
Nephrogenic systemic fibrosis	49.02	11.38	37	49111	3464	42568723
Interstitial lung disease	48.58	11.38	15	49133	78447	42493740
Product substitution issue	47.81	11.38	62	49086	11228	42560959
Thrombocytopenia	47.62	11.38	92	49056	190187	42382000
Neuroleptic malignant syndrome	47.13	11.38	87	49061	21385	42550802
Overweight	46.53	11.38	31	49117	2381	42569806
Psychomotor hyperactivity	46.13	11.38	60	49088	10898	42561289
Suicidal ideation	45.05	11.38	140	49008	48021	42524166
Somnolence	44.01	11.38	296	48852	140809	42431378
Anal inflammation	43.85	11.38	29	49119	2200	42569987
Pneumonia	43.41	11.38	297	48851	421852	42150335
Catatonia	42.89	11.38	44	49104	6195	42565992
Product adhesion issue	42.63	11.38	26	49122	1713	42570474
Miosis	42.26	11.38	64	49084	13382	42558805
SARS-CoV-2 test negative	42.14	11.38	26	49122	1749	42570438
Toxicity to various agents	41.49	11.38	425	48723	228711	42343476
Hypertensive emergency	41.36	11.38	23	49125	1274	42570913
Respiratory arrest	41.06	11.38	97	49051	28327	42543860
Neutropenia	40.49	11.38	108	49040	199323	42372864
Malignant neoplasm progression	39.50	11.38	40	49108	108360	42463827
Dyskinesia	39.27	11.38	89	49059	25301	42546886
Pancytopenia	38.99	11.38	47	49101	117696	42454491
Cardiac arrest	38.80	11.38	237	48911	109083	42463104
Hypertensive urgency	38.35	11.38	16	49132	465	42571722
Hepatic function abnormal	37.52	11.38	7	49141	51560	42520627
Peritonitis bacterial	37.44	11.38	43	49105	6872	42565315
Tardive dyskinesia	37.40	11.38	43	49105	6881	42565306
Hyperaesthesia	37.38	11.38	40	49108	5912	42566275
Emotional distress	36.32	11.38	66	49082	16027	42556160
Device failure	36.23	11.38	28	49120	2715	42569472
Toxic epidermal necrolysis	36.19	11.38	89	49059	26661	42545526
Kidney transplant rejection	35.70	11.38	47	49101	8636	42563551
Myelosuppression	35.44	11.38	3	49145	40458	42531729
Cytokine release syndrome	34.72	11.38	5	49143	44522	42527665
Cerebrovascular accident	34.71	11.38	211	48937	96949	42475238
Application site pruritus	34.66	11.38	22	49126	1556	42570631
Product use issue	34.26	11.38	177	48971	76574	42495613
Overdose	34.12	11.38	223	48925	105041	42467146
Inadequate analgesia	32.46	11.38	28	49120	3169	42569018
Drug ineffective for unapproved indication	32.46	11.38	122	49026	46041	42526146
Affect lability	32.39	11.38	31	49117	4013	42568174
Aplastic anaemia	32.12	11.38	54	49094	12330	42559857
Disease progression	32.11	11.38	74	49074	143582	42428605
Pyrexia	30.08	11.38	300	48848	393742	42178445
Hypotonia	29.55	11.38	45	49103	9454	42562733
Malignant catatonia	29.15	11.38	13	49135	446	42571741
General physical health deterioration	29.12	11.38	84	49064	151162	42421025
Social problem	29.08	11.38	18	49130	1218	42570969
Autonomic nervous system imbalance	29.05	11.38	26	49122	3090	42569097
Accidental overdose	28.98	11.38	85	49063	28245	42543942
Application site irritation	28.86	11.38	15	49133	725	42571462
Unresponsive to stimuli	28.18	11.38	90	49058	31313	42540874
Injury	27.84	11.38	72	49076	22244	42549943
Neutrophil count decreased	27.23	11.38	20	49128	63395	42508792
Application site erythema	27.13	11.38	23	49125	2543	42569644
Tic	26.52	11.38	22	49126	2361	42569826
Rheumatoid arthritis	26.47	11.38	8	49140	42432	42529755
Accident	26.43	11.38	35	49113	6468	42565719
Pulmonary embolism	26.41	11.38	62	49086	119550	42452637
Intestinal pseudo-obstruction	25.47	11.38	21	49127	2234	42569953
Hyperhidrosis	24.76	11.38	184	48964	90328	42481859
Seizure	24.40	11.38	229	48919	120332	42451855
Renal transplant	24.14	11.38	21	49127	2404	42569783
COVID-19	24.11	11.38	62	49086	115886	42456301
Abnormal behaviour	23.91	11.38	76	49072	26375	42545812
Accelerated hypertension	23.89	11.38	10	49138	293	42571894
Productive cough	23.82	11.38	15	49133	51552	42520635
Coordination abnormal	23.45	11.38	37	49111	8013	42564174
Drug screen positive	22.89	11.38	26	49122	4105	42568082
Device power source issue	22.67	11.38	12	49136	602	42571585
Sedation complication	22.67	11.38	22	49126	2897	42569290
Insomnia	22.63	11.38	222	48926	118031	42454156
Platelet count decreased	22.49	11.38	83	49065	138498	42433689
Drug tolerance	22.25	11.38	23	49125	3267	42568920
Galactorrhoea	21.91	11.38	11	49137	494	42571693
Attention deficit hyperactivity disorder	21.51	11.38	22	49126	3086	42569101
Drug withdrawal maintenance therapy	21.34	11.38	8	49140	174	42572013
Corneal reflex decreased	21.29	11.38	8	49140	175	42572012
Product prescribing issue	20.95	11.38	32	49116	6741	42565446
Pulmonary fibrosis	20.79	11.38	3	49145	26678	42545509
Tenderness	20.77	11.38	37	49111	8846	42563341
Hyperkinesia	20.55	11.38	18	49130	2080	42570107
Anger	20.53	11.38	46	49102	12972	42559215
Speech disorder	20.50	11.38	77	49071	29044	42543143
Lower respiratory tract infection	20.44	11.38	11	49137	41195	42530992
Poor quality sleep	20.40	11.38	38	49110	9402	42562785
C-reactive protein increased	20.37	11.38	26	49122	63534	42508653
Sepsis	20.03	11.38	141	49007	199193	42372994
White blood cell count decreased	20.03	11.38	63	49085	110333	42461854
Product administered to patient of inappropriate age	19.93	11.38	26	49122	4735	42567452
Oromandibular dystonia	19.85	11.38	11	49137	605	42571582
Natural killer cell count decreased	19.41	11.38	4	49144	6	42572181
Anhedonia	19.40	11.38	33	49115	7607	42564580
Mood altered	19.35	11.38	40	49108	10678	42561509
Tourette's disorder	19.29	11.38	6	49142	72	42572115
Pneumocystis jirovecii pneumonia	19.23	11.38	3	49145	25178	42547009
Labile hypertension	18.72	11.38	6	49142	80	42572107
Multiple organ dysfunction syndrome	18.59	11.38	54	49094	96981	42475206
Medical device site pain	18.51	11.38	6	49142	83	42572104
Paradoxical drug reaction	18.49	11.38	25	49123	4713	42567474
Hyponatraemia	18.34	11.38	58	49090	101404	42470783
Product preparation error	18.32	11.38	25	49123	4753	42567434
Myocardial infarction	18.27	11.38	221	48927	123788	42448399
Infection	18.26	11.38	67	49081	112001	42460186
Cardio-respiratory arrest	18.24	11.38	123	49025	58513	42513674
Prostate cancer	18.00	11.38	15	49133	44628	42527559
Stress cardiomyopathy	17.99	11.38	19	49129	2766	42569421
Pain	17.80	11.38	388	48760	244460	42327727
Gastrointestinal tract mucosal pigmentation	17.73	11.38	10	49138	569	42571618
Axillary pain	17.55	11.38	9	49139	423	42571764
Loss of consciousness	16.99	11.38	172	48976	92182	42480005
Implant site extravasation	16.96	11.38	9	49139	454	42571733
Brain injury	16.77	11.38	31	49117	7624	42564563
Hypoxic-ischaemic encephalopathy	16.69	11.38	25	49123	5177	42567010
Cardiac failure	16.68	11.38	65	49083	106791	42465396
Fibrosis	16.67	11.38	19	49129	3011	42569176
Posterior reversible encephalopathy syndrome	16.64	11.38	42	49106	12779	42559408
Arthralgia	16.56	11.38	154	48994	205084	42367103
Diarrhoea	16.56	11.38	405	48743	460444	42111743
Reaction to excipient	16.49	11.38	10	49138	652	42571535
Product preparation issue	16.48	11.38	12	49136	1063	42571124
Loss of libido	16.47	11.38	19	49129	3051	42569136
Intentional product misuse	16.45	11.38	125	49023	61775	42510412
Streptococcal infection	16.25	11.38	27	49121	6105	42566082
Colitis ulcerative	16.20	11.38	5	49143	26170	42546017
Skin induration	15.87	11.38	15	49133	1912	42570275
Depressed mood	15.77	11.38	61	49087	23323	42548864
Drooling	15.74	11.38	22	49126	4277	42567910
Self-destructive behaviour	15.58	11.38	8	49140	377	42571810
Lymphopenia	15.53	11.38	3	49145	21560	42550627
Mast cell degranulation present	15.51	11.38	5	49143	68	42572119
Agranulocytosis	15.43	11.38	8	49140	30604	42541583
Muscle spasticity	15.42	11.38	28	49120	6794	42565393
Double inlet left ventricle	15.31	11.38	4	49144	24	42572163
Rash	15.30	11.38	226	48922	276728	42295459
Autism spectrum disorder	15.21	11.38	18	49130	2970	42569217
Drug ineffective	15.19	11.38	879	48269	629318	41942869
Implant site pain	15.19	11.38	6	49142	151	42572036
Product compounding quality issue	15.17	11.38	4	49144	25	42572162
Drug abuse	15.12	11.38	186	48962	104585	42467602
Brief psychotic disorder with marked stressors	15.00	11.38	7	49141	267	42571920
Poisoning	14.93	11.38	44	49104	14655	42557532
Saccadic eye movement	14.83	11.38	6	49142	161	42572026
Left ventricular hypertrophy	14.78	11.38	33	49115	9286	42562901
Impulsive behaviour	14.71	11.38	16	49132	2409	42569778
Therapeutic product effect incomplete	14.69	11.38	38	49110	70901	42501286
Hyperbilirubinaemia	14.59	11.38	3	49145	20632	42551555
Accidental poisoning	14.49	11.38	12	49136	1284	42570903
Treatment noncompliance	14.19	11.38	83	49065	37589	42534598
Sprue-like enteropathy	14.16	11.38	9	49139	638	42571549
Septic shock	14.16	11.38	56	49092	91616	42480571
Incision site pain	14.14	11.38	14	49134	1889	42570298
Skin tightness	14.14	11.38	15	49133	2195	42569992
Subdural effusion	14.01	11.38	5	49143	94	42572093
Hepatitis	13.96	11.38	7	49141	27293	42544894
Lung disorder	13.96	11.38	21	49127	47902	42524285
Univentricular heart	13.90	11.38	4	49144	36	42572151
Respiratory rate decreased	13.78	11.38	17	49131	2928	42569259
Drug interaction	13.74	11.38	404	48744	266595	42305592
Renal artery stenosis	13.55	11.38	15	49133	2302	42569885
Autoimmune enteropathy	13.52	11.38	4	49144	40	42572147
Hydrocele male infected	13.52	11.38	4	49144	40	42572147
Restlessness	13.42	11.38	68	49080	29181	42543006
Frequent bowel movements	13.41	11.38	4	49144	21403	42550784
Psoriatic arthropathy	13.39	11.38	6	49142	24961	42547226
Akathisia	13.32	11.38	34	49114	10417	42561770
Renal tubular atrophy	13.29	11.38	12	49136	1443	42570744
Nervousness	13.26	11.38	40	49108	13492	42558695
Drug eruption	13.25	11.38	5	49143	23070	42549117
Metastases to eye	13.24	11.38	5	49143	111	42572076
Disseminated intravascular coagulation	13.23	11.38	6	49142	24788	42547399
Product quality issue	13.18	11.38	48	49100	17834	42554353
Obsessive-compulsive disorder	13.16	11.38	26	49122	6717	42565470
Harlequin syndrome	13.15	11.38	3	49145	9	42572178
Intentional self-injury	13.12	11.38	43	49105	15159	42557028
Tremor	13.09	11.38	170	48978	96759	42475428
Metabolic alkalosis	12.98	11.38	14	49134	2087	42570100
Skin hypertrophy	12.89	11.38	16	49132	2773	42569414
Inflammation	12.88	11.38	12	49136	33835	42538352
Cytomegalovirus infection	12.84	11.38	11	49137	32295	42539892
Renal injury	12.70	11.38	37	49111	12243	42559944
Lymphocele	12.66	11.38	12	49136	1535	42570652
Infusion site mass	12.60	11.38	7	49141	387	42571800
Joint contracture	12.55	11.38	14	49134	2167	42570020
Rash maculo-papular	12.37	11.38	15	49133	37488	42534699
Haemophagocytic lymphohistiocytosis	12.18	11.38	3	49145	18219	42553968
Hepatic cytolysis	12.14	11.38	8	49140	26836	42545351
Torticollis	11.93	11.38	11	49137	1359	42570828
Abdominal compartment syndrome	11.88	11.38	10	49138	1095	42571092
Device infusion issue	11.85	11.38	10	49138	1098	42571089
Anti-glomerular basement membrane disease	11.69	11.38	4	49144	66	42572121
Post transplant distal limb syndrome	11.63	11.38	7	49141	450	42571737
Alopecia	11.60	11.38	10	49138	29266	42542921
Psychotic symptom	11.51	11.38	14	49134	2376	42569811
Medical device site infection	11.47	11.38	6	49142	294	42571893
Pneumonitis	11.46	11.38	19	49129	41699	42530488
Clonus	11.41	11.38	17	49131	3503	42568684

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	953.41	10.02	1201	111034	241180	110235884
Temperature regulation disorder	598.68	10.02	282	111953	12544	110464520
Food allergy	476.08	10.02	280	111955	19668	110457396
Drug withdrawal syndrome	451.70	10.02	346	111889	37708	110439356
Bradycardia	391.19	10.02	623	111612	154894	110322170
Immunodeficiency	350.64	10.02	301	111934	38537	110438527
Overdose	306.47	10.02	710	111525	233084	110243980
Hyperhidrosis	299.17	10.02	616	111619	186682	110290382
Coeliac disease	292.66	10.02	285	111950	42902	110434162
Hypertensive crisis	281.33	10.02	218	112017	24154	110452910
Hypertension	233.29	10.02	1080	111155	509004	109968060
Withdrawal syndrome	229.50	10.02	216	112019	31164	110445900
Foetal death	221.98	10.02	160	112075	15885	110461179
Fluid retention	215.60	10.02	362	111873	93945	110383119
Aggression	212.75	10.02	281	111954	58929	110418135
Mental status changes	208.05	10.02	317	111918	75805	110401259
Withdrawal hypertension	207.51	10.02	54	112181	369	110476695
Cardiac failure congestive	207.05	10.02	467	111768	150533	110326531
Suspected suicide	199.90	10.02	147	112088	15052	110462012
Respiratory depression	199.81	10.02	202	112033	31799	110445265
Toxicity to various agents	191.27	10.02	978	111257	479577	109997487
Rash erythematous	186.89	10.02	314	111921	81518	110395546
Drug dependence	183.75	10.02	240	111995	49780	110427284
Synovitis	181.64	10.02	30	112205	274062	110203002
Hypotension	176.67	10.02	1019	111216	522830	109954234
Intentional product misuse	167.85	10.02	398	111837	132506	110344558
Upper respiratory tract infection	160.16	10.02	388	111847	130940	110346124
Hand deformity	149.10	10.02	22	112213	218484	110258580
Sinus bradycardia	148.43	10.02	166	112069	29317	110447747
Pemphigus	138.82	10.02	25	112210	214545	110262519
Arthropathy	135.56	10.02	61	112174	287461	110189603
Anti-cyclic citrullinated peptide antibody positive	129.68	10.02	16	112219	181968	110295096
Accidental exposure to product by child	127.11	10.02	63	112172	3135	110473929
Systemic lupus erythematosus	126.25	10.02	50	112185	254288	110222776
Glossodynia	125.30	10.02	35	112200	221969	110255095
Pericarditis	120.98	10.02	36	112199	219078	110257986
Neovascularisation	115.69	10.02	49	112186	1688	110475376
Agitation	115.03	10.02	312	111923	112739	110364325
Paradoxical drug reaction	111.52	10.02	87	112148	9730	110467334
Cardiac arrest	110.75	10.02	444	111791	196309	110280755
Cerebrovascular accident	110.08	10.02	419	111816	180865	110296199
Duodenal ulcer perforation	106.05	10.02	25	112210	177675	110299389
Somnolence	105.60	10.02	587	111648	296862	110180202
Bursitis	104.77	10.02	330	111905	129588	110347476
Respiratory arrest	102.85	10.02	200	112035	58099	110418965
Sedation	102.78	10.02	222	112013	69461	110407603
Victim of child abuse	100.54	10.02	40	112195	1171	110475893
Anti-neutrophil cytoplasmic antibody positive vasculitis	98.61	10.02	64	112171	5353	110471711
Lethargy	96.95	10.02	260	111975	93316	110383748
Poisoning	96.71	10.02	133	112102	28972	110448092
Constipation	95.49	10.02	656	111579	357130	110119934
Psoriatic arthropathy	95.49	10.02	40	112195	196721	110280343
Alopecia	95.27	10.02	139	112096	364614	110112450
Wound	94.04	10.02	61	112174	234376	110242688
Lower respiratory tract infection	93.84	10.02	66	112169	243040	110234024
Epidural lipomatosis	92.01	10.02	44	112191	2023	110475041
Oppositional defiant disorder	91.86	10.02	30	112205	488	110476576
Body tinea	91.05	10.02	44	112191	2071	110474993
Folliculitis	89.93	10.02	29	112206	167624	110309440
Neutropenia	88.16	10.02	153	112082	374467	110102597
Arthralgia	87.80	10.02	450	111785	779182	109697882
Blood pressure inadequately controlled	87.48	10.02	68	112167	7565	110469499
Prescribed overdose	87.38	10.02	240	111995	87341	110389723
Febrile neutropenia	86.41	10.02	117	112118	316650	110160414
Hypertensive emergency	85.13	10.02	49	112186	3302	110473762
Muscle injury	83.64	10.02	20	112215	140787	110336277
Nephrogenic systemic fibrosis	83.53	10.02	58	112177	5425	110471639
Impaired healing	83.33	10.02	48	112187	196669	110280395
Back pain	81.21	10.02	649	111586	370347	110106717
Myocardial infarction	81.20	10.02	398	111837	191685	110285379
Psychomotor hyperactivity	80.29	10.02	101	112134	20176	110456888
Irritable bowel syndrome	78.69	10.02	34	112201	164181	110312883
Miosis	78.43	10.02	104	112131	21879	110455185
C-reactive protein abnormal	77.87	10.02	18	112217	129677	110347387
Malignant neoplasm progression	76.24	10.02	41	112194	174526	110302538
Cardio-respiratory arrest	73.84	10.02	272	111963	115564	110361500
Helicobacter infection	73.37	10.02	47	112188	181830	110295234
Child abuse	72.54	10.02	29	112206	860	110476204
Rheumatoid factor positive	71.97	10.02	22	112213	131618	110345446
Malignant catatonia	71.71	10.02	27	112208	679	110476385
Interstitial lung disease	69.76	10.02	27	112208	139307	110337757
Blood pressure increased	69.64	10.02	475	111760	257898	110219166
Choreoathetosis	69.12	10.02	34	112201	1664	110475400
Poor quality sleep	68.46	10.02	111	112124	27966	110449098
Decreased eye contact	68.31	10.02	28	112207	887	110476177
Infection susceptibility increased	68.12	10.02	47	112188	4351	110472713
Swelling	67.56	10.02	161	112074	350880	110126184
Homicidal ideation	66.38	10.02	43	112192	3584	110473480
Unresponsive to stimuli	64.82	10.02	176	112059	63614	110413450
Gastrointestinal disorder	64.33	10.02	91	112144	241861	110235203
Hypertensive encephalopathy	63.90	10.02	29	112206	1182	110475882
Inhibitory drug interaction	63.15	10.02	47	112188	4900	110472164
Rheumatic fever	62.62	10.02	23	112212	122556	110354508
Therapeutic product effect decreased	60.96	10.02	96	112139	244220	110232844
C-reactive protein increased	60.93	10.02	79	112156	217840	110259224
Intentional product use issue	60.36	10.02	99	112136	247807	110229257
Discomfort	59.86	10.02	78	112157	214629	110262435
Nasopharyngitis	59.60	10.02	203	112032	394158	110082906
Suicidal ideation	56.88	10.02	217	112018	93720	110383344
Hypertensive urgency	55.71	10.02	26	112209	1131	110475933
Dystonia	54.92	10.02	96	112139	25709	110451355
Irritability	54.80	10.02	138	112097	47671	110429393
Accidental overdose	54.66	10.02	145	112090	51689	110425375
Implant site extravasation	54.66	10.02	24	112211	904	110476160
Distributive shock	53.76	10.02	46	112189	5858	110471206
Facet joint syndrome	53.26	10.02	16	112219	96812	110380252
Glucose tolerance impaired	52.30	10.02	57	112178	9780	110467284
Inflammation	52.04	10.02	72	112163	193166	110283898
Application site pruritus	51.94	10.02	39	112196	4121	110472943
Maternal exposure during pregnancy	51.36	10.02	114	112121	254769	110222295
Seizure	51.14	10.02	392	111843	220793	110256271
Product tampering	51.14	10.02	19	112216	460	110476604
Liver disorder	50.55	10.02	42	112193	142201	110334863
Blood prolactin increased	50.28	10.02	40	112195	4602	110472462
Ill-defined disorder	50.19	10.02	51	112184	156802	110320262
General physical health deterioration	49.76	10.02	242	111993	425053	110052011
Toxic epidermal necrolysis	49.35	10.02	148	112087	56579	110420485
Catatonia	49.12	10.02	59	112176	11241	110465823
Juvenile idiopathic arthritis	49.07	10.02	44	112191	5963	110471101
Hepatic function abnormal	48.67	10.02	15	112220	89280	110387784
Hyperaesthesia	48.47	10.02	67	112168	14660	110462404
Application site irritation	48.35	10.02	28	112207	1909	110475155
Neutrophil count decreased	47.76	10.02	32	112203	120909	110356155
Peritonitis bacterial	47.44	10.02	56	112179	10477	110466587
Product use issue	47.24	10.02	504	111731	311191	110165873
Dissociation	47.13	10.02	54	112181	9788	110467276
Brain injury	46.92	10.02	63	112172	13413	110463651
Decreased immune responsiveness	46.49	10.02	53	112182	9553	110467511
Dyskinesia	46.44	10.02	136	112099	51310	110425754
Abdominal discomfort	46.14	10.02	224	112011	393634	110083430
Musculoskeletal stiffness	45.77	10.02	139	112096	279683	110197381
Trismus	45.55	10.02	44	112191	6552	110470512
Depressed level of consciousness	45.55	10.02	230	112005	112048	110365016
Drug ineffective for unapproved indication	45.53	10.02	216	112019	102622	110374442
Crying	45.29	10.02	88	112147	25540	110451524
Application site rash	44.73	10.02	29	112206	2421	110474643
Diarrhoea	44.56	10.02	852	111383	1138653	109338411
Condition aggravated	43.76	10.02	506	111729	734330	109742734
Disease progression	43.76	10.02	116	112119	243918	110233146
Medical device site pain	43.39	10.02	16	112219	379	110476685
Left ventricular hypertrophy	43.21	10.02	60	112175	13184	110463880
Intentional overdose	42.07	10.02	254	111981	132247	110344817
Product prescribing error	41.92	10.02	131	112104	51200	110425864
Asthma	41.87	10.02	413	111822	249878	110227186
Anal inflammation	41.81	10.02	28	112207	2468	110474596
Pulmonary fibrosis	41.65	10.02	26	112209	102016	110375048
Arthritis	41.65	10.02	66	112169	167520	110309544
Lip dry	41.55	10.02	25	112210	100058	110377006
Anxiety	41.21	10.02	533	111702	344545	110132519
Lung disorder	40.99	10.02	75	112160	179972	110297092
Drug screen positive	40.99	10.02	41	112194	6369	110470695
Neuroleptic malignant syndrome	40.82	10.02	100	112135	33959	110443105
Peripheral swelling	40.56	10.02	242	111993	403792	110073272
Kidney transplant rejection	40.15	10.02	55	112180	11932	110465132
Cytokine release syndrome	39.80	10.02	11	112224	70295	110406769
Product substitution issue	39.31	10.02	78	112157	22983	110454081
Extrapyramidal disorder	39.21	10.02	89	112146	28778	110448286
Tardive dyskinesia	39.14	10.02	58	112177	13521	110463543
White blood cell count decreased	38.92	10.02	112	112123	229278	110247786
Intestinal angioedema	38.88	10.02	20	112215	1077	110475987
Acute motor-sensory axonal neuropathy	38.59	10.02	16	112219	522	110476542
Loss of consciousness	38.40	10.02	335	111900	195971	110281093
SARS-CoV-2 test negative	38.12	10.02	25	112210	2128	110474936
Mobility decreased	38.07	10.02	119	112116	237303	110239761
Emotional distress	38.06	10.02	116	112119	44731	110432333
Night sweats	38.03	10.02	48	112187	133935	110343129
Erythema	37.72	10.02	457	111778	290990	110186074
Bruxism	37.70	10.02	35	112200	4959	110472105
Apnoea	37.53	10.02	57	112178	13582	110463482
Swollen joint count increased	37.48	10.02	19	112216	83642	110393422
Wheezing	37.44	10.02	133	112102	255097	110221967
Coronary artery disease	37.31	10.02	158	112077	71532	110405532
COVID-19	37.10	10.02	126	112109	244934	110232130
Malignant hypertension	36.33	10.02	22	112213	1629	110475435
Pneumonia	36.25	10.02	649	111586	876065	109600999
Gastrointestinal tract mucosal pigmentation	36.03	10.02	20	112215	1257	110475807
Akathisia	35.55	10.02	63	112172	17050	110460014
Breast cancer stage III	35.40	10.02	18	112217	79099	110397965
Anuria	35.26	10.02	77	112158	24264	110452800
Acute myocardial infarction	34.95	10.02	173	112062	83604	110393460
Claustrophobia	34.64	10.02	21	112214	1558	110475506
Application site erythema	34.26	10.02	35	112200	5575	110471489
Aplastic anaemia	34.19	10.02	76	112159	24232	110452832
Sinusitis	33.43	10.02	171	112064	296517	110180547
Joint swelling	33.38	10.02	288	111947	442557	110034507
Hypoventilation	33.19	10.02	41	112194	8040	110469024
Blister	33.01	10.02	119	112116	227257	110249807
Rash	32.59	10.02	612	111623	820352	109656712
Osteoarthritis	32.59	10.02	87	112148	182536	110294528
Hypothermia	32.34	10.02	78	112157	26224	110450840
Mucosal erosion	32.02	10.02	25	112210	2799	110474265
Retching	32	10.02	71	112164	22611	110454453
Hepatitis	31.49	10.02	27	112208	90027	110387037
Hypotonia	31.48	10.02	57	112178	15688	110461376
Joint range of motion decreased	31.21	10.02	47	112188	121785	110355279
Peripheral venous disease	30.93	10.02	24	112211	84093	110392971
Grip strength decreased	30.61	10.02	22	112213	80152	110396912
Serotonin syndrome	30.50	10.02	130	112105	59023	110418041
Pancytopenia	30.23	10.02	110	112125	209503	110267561
Posterior reversible encephalopathy syndrome	30.07	10.02	89	112146	33772	110443292
Skin hypertrophy	29.94	10.02	31	112204	5016	110472048
Pneumocystis jirovecii pneumonia	29.84	10.02	4	112231	42731	110434333
Colitis ulcerative	29.84	10.02	21	112214	77342	110399722
Skin induration	29.75	10.02	29	112206	4366	110472698
Adulterated product	29.64	10.02	17	112218	1138	110475926
Malaise	29.45	10.02	492	111743	671327	109805737
Live birth	29.35	10.02	17	112218	69467	110407597
Tremor	29.23	10.02	324	111911	201908	110275156
Urinary incontinence	29.21	10.02	112	112123	48475	110428589
Blood cholesterol increased	28.65	10.02	94	112141	184691	110292373
Anhedonia	28.52	10.02	54	112181	15374	110461690
Blepharospasm	28.51	10.02	10	112225	54841	110422223
Osteonecrosis of jaw	28.16	10.02	7	112228	48010	110429054
Product compounding quality issue	27.97	10.02	7	112228	40	110477024
Psoriasis	27.95	10.02	240	111995	139753	110337311
Taste disorder	27.61	10.02	16	112219	65371	110411693
Anger	27.38	10.02	60	112175	18947	110458117
Hyperreflexia	26.61	10.02	40	112195	9445	110467619
Productive cough	26.56	10.02	47	112188	114258	110362806
Product adhesion issue	26.52	10.02	23	112212	2983	110474081
Oromandibular dystonia	26.20	10.02	16	112219	1203	110475861
Dialysis	26.10	10.02	60	112175	19559	110457505
Chronic kidney disease	25.99	10.02	149	112086	76142	110400922
Abnormal behaviour	25.99	10.02	93	112142	38946	110438118
Medical device site discharge	25.93	10.02	7	112228	56	110477008
Epilepsy with myoclonic-atonic seizures	25.87	10.02	8	112227	108	110476956
Nodal rhythm	25.86	10.02	24	112211	3399	110473665
Feeling of despair	25.60	10.02	25	112210	3773	110473291
Pulse abnormal	25.55	10.02	26	112209	4123	110472941
Tic	25.45	10.02	24	112211	3469	110473595
Overweight	25.27	10.02	32	112203	6432	110470632
Hyperlipidaemia	25.24	10.02	87	112148	35761	110441303
Liver injury	25.10	10.02	74	112161	150339	110326725
Autonomic nervous system imbalance	24.83	10.02	30	112205	5750	110471314
Basal ganglion degeneration	24.79	10.02	11	112224	425	110476639
Bone density decreased	24.67	10.02	52	112183	15990	110461074
Device power source issue	24.62	10.02	16	112219	1341	110475723
Anaesthesia	24.31	10.02	12	112223	592	110476472
Neoplasm progression	24.30	10.02	18	112217	64577	110412487
Device infusion issue	24.27	10.02	22	112213	3023	110474041
Mood swings	24.24	10.02	64	112171	22748	110454316
Loss of personal independence in daily activities	24.18	10.02	75	112160	149945	110327119
Device failure	24.04	10.02	33	112202	7174	110469890
Rash maculo-papular	23.89	10.02	24	112211	74198	110402866
Attention deficit hyperactivity disorder	23.83	10.02	26	112209	4465	110472599
Somatic symptom disorder	23.58	10.02	22	112213	3137	110473927
Stomatitis	23.49	10.02	169	112066	270073	110206991
Acute myeloid leukaemia	23.45	10.02	5	112230	38105	110438959
Pain	23.25	10.02	1188	111047	953767	109523297
Musculoskeletal pain	22.64	10.02	102	112133	182921	110294143
Fibromyalgia	22.51	10.02	93	112142	170816	110306248
Abdominal pain upper	22.48	10.02	236	111999	348875	110128189
Sleep disorder due to general medical condition, insomnia type	22.31	10.02	46	112189	105597	110371467
Cytomegalovirus infection	22.04	10.02	14	112221	54430	110422634
Medication error	21.75	10.02	182	112053	105184	110371880
Platelet count decreased	21.56	10.02	141	112094	230302	110246762
Speech disorder	21.47	10.02	121	112114	61448	110415616
Drug eruption	21.45	10.02	14	112221	53645	110423419
Haematochezia	21.40	10.02	54	112181	115470	110361594
Treatment noncompliance	21.33	10.02	137	112098	72853	110404211
Drooling	21.31	10.02	31	112204	7108	110469956
Impaired quality of life	21.27	10.02	73	112162	29944	110447120
Drug interaction	21.24	10.02	661	111574	499522	109977542
Neutropenic sepsis	21.18	10.02	3	112232	30743	110446321
Accelerated hypertension	21.17	10.02	12	112223	785	110476279
Injection site abscess	21.12	10.02	17	112218	1989	110475075
Accident	21.07	10.02	39	112196	10913	110466151
Frequent bowel movements	20.86	10.02	25	112210	71365	110405699
Epilepsy	20.85	10.02	44	112191	100165	110376899
Atrioventricular block second degree	20.84	10.02	33	112202	8148	110468916
Renin decreased	20.78	10.02	7	112228	126	110476938
Systolic dysfunction	20.76	10.02	24	112211	4391	110472673
Reaction to excipient	20.73	10.02	17	112218	2042	110475022
Blood aldosterone increased	20.61	10.02	8	112227	219	110476845
Intestinal pseudo-obstruction	20.61	10.02	21	112214	3335	110473729
Application site discolouration	20.60	10.02	13	112222	1036	110476028
Renal artery stenosis	20.52	10.02	22	112213	3704	110473360
Implant site infection	20.41	10.02	17	112218	2086	110474978
Urticaria	19.94	10.02	217	112018	318640	110158424
Hepatic cytolysis	19.87	10.02	16	112219	55037	110422027
Implant site pain	19.64	10.02	17	112218	2198	110474866
Onychomadesis	19.53	10.02	11	112224	45652	110431412
Nail disorder	19.50	10.02	18	112217	57917	110419147
Renal transplant	19.41	10.02	20	112215	3218	110473846
Eczema	19.39	10.02	27	112208	72266	110404798
Fibrous dysplasia of jaw	19.19	10.02	4	112231	8	110477056
Coma scale abnormal	19.18	10.02	35	112200	9691	110467373
Norepinephrine increased	19.07	10.02	6	112229	86	110476978
Alanine aminotransferase increased	18.99	10.02	109	112126	183664	110293400
Primary hyperaldosteronism	18.99	10.02	8	112227	272	110476792
Respiratory tract infection	18.96	10.02	27	112208	71590	110405474
Mood altered	18.81	10.02	56	112179	21319	110455745
Hypercholesterolaemia	18.80	10.02	40	112195	90797	110386267
Vascular stenosis	18.77	10.02	11	112224	767	110476297
Sympathomimetic effect	18.67	10.02	7	112228	174	110476890
Retrograde amnesia	18.65	10.02	11	112224	776	110476288
Electrocardiogram QRS complex prolonged	18.64	10.02	41	112194	12980	110464084
Restlessness	18.59	10.02	109	112126	56150	110420914
Product administered to patient of inappropriate age	18.55	10.02	31	112204	8005	110469059
Bronchiectasis	18.38	10.02	7	112228	36486	110440578
Drug abuse	18.29	10.02	267	111968	177144	110299920
Injection site erythema	18.24	10.02	43	112192	94133	110382931
Tissue infiltration	18.20	10.02	12	112223	1031	110476033
Croup infectious	18.12	10.02	12	112223	1038	110476026
Muscle contracture	18.03	10.02	18	112217	2790	110474274
Wound infection	17.94	10.02	45	112190	96420	110380644
Drug withdrawal headache	17.91	10.02	6	112229	106	110476958
Prostate cancer	17.70	10.02	8	112227	37633	110439431
Agranulocytosis	17.65	10.02	22	112213	61738	110415326
Therapeutic product effect incomplete	17.54	10.02	144	112091	223661	110253403
Rhabdomyolysis	17.43	10.02	193	112042	120208	110356856
Renal injury	17.40	10.02	50	112185	18663	110458401
Autism spectrum disorder	17.38	10.02	15	112220	1933	110475131
Electrocardiogram QT prolonged	17.34	10.02	178	112057	108782	110368282
Atrioventricular block first degree	17.29	10.02	42	112193	14183	110462881
Bone marrow failure	17.18	10.02	20	112215	57828	110419236
Iliac artery stenosis	17.04	10.02	7	112228	223	110476841
Purpura	17.01	10.02	59	112176	24329	110452735
Pruritus	16.91	10.02	455	111780	581105	109895959
Infusion site mass	16.84	10.02	14	112221	1714	110475350
Cancer pain	16.82	10.02	27	112208	6745	110470319
Type 2 diabetes mellitus	16.80	10.02	108	112127	177124	110299940
Medical device site infection	16.78	10.02	10	112225	719	110476345
Lymphopenia	16.72	10.02	10	112225	40160	110436904
Pulse absent	16.67	10.02	36	112199	11256	110465808
Abortion spontaneous	16.57	10.02	7	112228	34275	110442789
Hypoxic-ischaemic encephalopathy	16.39	10.02	31	112204	8816	110468248
Uterine enlargement	16.38	10.02	11	112224	974	110476090
Incision site pain	16.38	10.02	18	112217	3117	110473947
Tachycardia	16.38	10.02	322	111913	226323	110250741
Feeling abnormal	16.34	10.02	266	111969	180445	110296619
Pernicious anaemia	16.23	10.02	10	112225	764	110476300
Hyperkinesia	16.15	10.02	18	112217	3166	110473898
Mast cell degranulation present	16.13	10.02	5	112230	68	110476996
Pain in jaw	15.96	10.02	17	112218	51160	110425904
Pathergy reaction	15.87	10.02	5	112230	72	110476992
Secondary hypertension	15.81	10.02	9	112226	594	110476470
Genital erosion	15.80	10.02	10	112225	801	110476263
Affective disorder	15.65	10.02	35	112200	11206	110465858
Pneumonitis	15.59	10.02	34	112201	76497	110400567
Blood potassium increased	15.57	10.02	71	112164	33178	110443886
Change in seizure presentation	15.54	10.02	10	112225	824	110476240
Application site papules	15.50	10.02	5	112230	78	110476986
Rheumatoid arthritis	15.49	10.02	406	111829	299207	110177857
Renal tubular atrophy	15.37	10.02	15	112220	2261	110474803
Galactorrhoea	15.35	10.02	20	112215	4135	110472929
Melaena	15.32	10.02	29	112206	68728	110408336
Basal cell carcinoma	15.31	10.02	14	112221	45256	110431808
Implant site discharge	15.26	10.02	6	112229	170	110476894
Colitis	15.21	10.02	53	112182	102270	110374794
Respiratory moniliasis	15.07	10.02	8	112227	460	110476604
Deep vein thrombosis postoperative	15.06	10.02	23	112212	59268	110417796
Infection	14.95	10.02	268	111967	361932	110115132
Pulmonary oedema	14.87	10.02	162	112073	100497	110376567
Skin tightness	14.80	10.02	23	112212	5590	110471474
Pregnancy	14.80	10.02	18	112217	51049	110426015
Drug-induced liver injury	14.79	10.02	67	112168	120000	110357064
Pulmonary embolism	14.61	10.02	143	112092	214331	110262733
Infusion related reaction	14.51	10.02	286	111949	380876	110096188
Catheter site granuloma	14.49	10.02	5	112230	97	110476967
Kidney fibrosis	14.48	10.02	20	112215	4372	110472692
Feeling of body temperature change	14.46	10.02	24	112211	6164	110470900
Fibrosis	14.44	10.02	27	112208	7615	110469449
Vision blurred	14.43	10.02	197	112038	128825	110348239
Human ehrlichiosis	14.39	10.02	9	112226	706	110476358
Haemophagocytic lymphohistiocytosis	14.39	10.02	7	112228	31552	110445512
Drug ineffective	14.38	10.02	1757	110478	1518783	108958281
Impaired work ability	14.35	10.02	59	112176	26360	110450704
Respiratory rate decreased	14.26	10.02	24	112211	6234	110470830
Saccadic eye movement	14.24	10.02	6	112229	204	110476860
Breast cancer stage II	14.21	10.02	5	112230	27370	110449694
Obsessive-compulsive disorder	14.20	10.02	26	112209	7215	110469849
Sleep disorder	14.15	10.02	131	112104	198513	110278551
Sinus arrhythmia	14.10	10.02	14	112221	2156	110474908
Skin disorder	14.09	10.02	83	112152	42830	110434234
Chronic sinusitis	14.06	10.02	4	112231	25080	110451984
Headache	14.04	10.02	1058	111177	881319	109595745
Brief psychotic disorder with marked stressors	14.04	10.02	7	112228	353	110476711
Chest discomfort	14.01	10.02	111	112124	173737	110303327
Subdural effusion	13.99	10.02	5	112230	108	110476956
Joint injury	13.97	10.02	12	112223	39982	110437082
Peritoneal dialysis complication	13.97	10.02	15	112220	2531	110474533
BRASH syndrome	13.88	10.02	18	112217	3705	110473359
Glomerulonephritis rapidly progressive	13.86	10.02	14	112221	2201	110474863
Focal segmental glomerulosclerosis	13.86	10.02	19	112216	4126	110472938
Corneal reflex decreased	13.82	10.02	8	112227	545	110476519
Blood pressure decreased	13.81	10.02	178	112057	114913	110362151
Bone erosion	13.80	10.02	16	112219	46355	110430709
Product prescribing issue	13.74	10.02	36	112199	12736	110464328
Short-bowel syndrome	13.71	10.02	9	112226	767	110476297
Pyrexia	13.66	10.02	759	111476	897506	109579558
Inadequate analgesia	13.66	10.02	21	112214	5056	110472008
Exposure to allergen	13.66	10.02	8	112227	557	110476507
Death	13.58	10.02	852	111383	698017	109779047
Cardiac hypertrophy	13.47	10.02	13	112222	1934	110475130
Drug intolerance	13.44	10.02	312	111923	406200	110070864
Nervousness	13.23	10.02	73	112162	36778	110440286
Hypersomnia	13.20	10.02	60	112175	28001	110449063
Pulmonary renal syndrome	13.05	10.02	9	112226	832	110476232
Myoclonus	12.96	10.02	67	112168	32931	110444133
Gun shot wound	12.95	10.02	10	112225	1102	110475962
Blood bilirubin increased	12.94	10.02	37	112198	75935	110401129
Skin fibrosis	12.93	10.02	11	112224	1389	110475675
Onychomycosis	12.93	10.02	12	112223	38519	110438545
Product preparation issue	12.89	10.02	15	112220	2764	110474300
Supraventricular tachycardia	12.84	10.02	54	112181	24368	110452696
Fear	12.76	10.02	52	112183	23141	110453923
Anaemia	12.71	10.02	441	111794	546645	109930419
Toxic skin eruption	12.70	10.02	6	112229	27509	110449555
X-ray abnormal	12.64	10.02	12	112223	38105	110438959
Labelled drug-drug interaction medication error	12.62	10.02	7	112228	29295	110447769
Labile blood pressure	12.58	10.02	14	112221	2457	110474607
Hyperthyroidism	12.58	10.02	7	112228	29254	110447810
Mydriasis	12.45	10.02	50	112185	22107	110454957
Device expulsion	12.43	10.02	8	112227	30883	110446181
Liver function test increased	12.41	10.02	47	112188	88501	110388563
Peau d'orange	12.38	10.02	6	112229	284	110476780
Tumour lysis syndrome	12.36	10.02	8	112227	30793	110446271
Renal failure	12.28	10.02	309	111926	226265	110250799
Hyperbilirubinaemia	12.26	10.02	8	112227	30663	110446401
Transaminases increased	12.23	10.02	29	112206	63361	110413703
Hallucination	12.22	10.02	157	112078	101275	110375789
Hypervolaemia	12.17	10.02	89	112146	49371	110427693
Tracheostomy	12.11	10.02	11	112224	1516	110475548
Respiratory failure	12.07	10.02	295	111940	215037	110262027
Page kidney	12.03	10.02	4	112231	69	110476995
Maternal use of illicit drugs	12.01	10.02	3	112232	17	110477047
Trichostasis spinulosa	12.01	10.02	3	112232	17	110477047
C-reactive protein	12.01	10.02	8	112227	30323	110446741
Appendicitis	11.97	10.02	7	112228	28457	110448607
Therapeutic drug monitoring analysis incorrectly performed	11.96	10.02	8	112227	704	110476360
Respiratory acidosis	11.95	10.02	36	112199	13790	110463274
Gamma-glutamyltransferase increased	11.87	10.02	28	112207	61281	110415783
Bladder cancer	11.82	10.02	3	112232	20289	110456775
Implant site mass	11.77	10.02	4	112231	74	110476990
Osteoporosis	11.74	10.02	47	112188	87105	110389959
Autoimmune enteropathy	11.72	10.02	4	112231	75	110476989
Renal transplant failure	11.66	10.02	14	112221	2666	110474398
Rhinorrhoea	11.65	10.02	59	112176	102607	110374457
Aspartate aminotransferase increased	11.59	10.02	105	112130	159831	110317233
Medical device site erythema	11.53	10.02	4	112231	79	110476985
Screaming	11.50	10.02	19	112216	4862	110472202
Gait inability	11.50	10.02	86	112149	136290	110340774
Psychogenic seizure	11.37	10.02	13	112222	2351	110474713
Multiple sclerosis relapse	11.36	10.02	21	112214	50219	110426845
Rash pruritic	11.33	10.02	56	112179	98013	110379051
Foreign body reaction	11.30	10.02	5	112230	192	110476872
Uveitis	11.21	10.02	4	112231	21706	110455358
Hip arthroplasty	11.20	10.02	25	112210	55788	110421276
Delirium	11.20	10.02	196	112039	134829	110342235
Gastric ileus	11.12	10.02	3	112232	24	110477040
Medical device site swelling	11.04	10.02	4	112231	90	110476974
Paraesthesia	10.97	10.02	206	112029	276315	110200749
Drug clearance	10.96	10.02	4	112231	92	110476972
Alcoholism	10.92	10.02	16	112219	3691	110473373
Accidental poisoning	10.83	10.02	13	112222	2474	110474590
Retinopathy hypertensive	10.83	10.02	7	112228	581	110476483
Drug detoxification	10.83	10.02	7	112228	581	110476483
Stress cardiomyopathy	10.82	10.02	38	112197	15768	110461296
Joint contracture	10.82	10.02	13	112222	2478	110474586
Knee arthroplasty	10.80	10.02	32	112203	64916	110412148
Impulsive behaviour	10.79	10.02	15	112220	3300	110473764
Metastases to liver	10.76	10.02	12	112223	35374	110441690
Labile hypertension	10.71	10.02	7	112228	592	110476472
Drug resistance	10.71	10.02	26	112209	56348	110420716
Human herpesvirus 6 infection reactivation	10.70	10.02	9	112226	1120	110475944
Hypertrichosis	10.69	10.02	11	112224	1767	110475297
Cognitive disorder	10.68	10.02	49	112186	87462	110389602
Paranoia	10.64	10.02	48	112187	22326	110454738
Cerebellar atrophy	10.62	10.02	10	112225	1443	110475621
Blood pressure systolic abnormal	10.61	10.02	6	112229	24844	110452220
Sciatica	10.54	10.02	53	112182	92346	110384718
Graft versus host disease	10.54	10.02	3	112232	18803	110458261
Implant site hypersensitivity	10.52	10.02	3	112232	30	110477034
Hepatitis acute	10.50	10.02	3	112232	18763	110458301
Psychotic symptom	10.41	10.02	16	112219	3851	110473213
Hyperthermia	10.39	10.02	46	112189	21226	110455838
Pulseless electrical activity	10.38	10.02	39	112196	16718	110460346
Encephalomalacia	10.34	10.02	10	112225	1492	110475572
Foot deformity	10.33	10.02	21	112214	48459	110428605
Rhinitis	10.28	10.02	5	112230	22540	110454524
Metastases to bone	10.26	10.02	10	112225	31362	110445702
Adrenal insufficiency	10.24	10.02	17	112218	42373	110434691
Prescribed underdose	10.20	10.02	33	112202	65141	110411923
Chloasma	10.19	10.02	4	112231	113	110476951
Cerebral atrophy	10.18	10.02	26	112209	9059	110468005
Tendonitis	10.16	10.02	7	112228	26076	110450988
Intercepted medication error	10.12	10.02	9	112226	1207	110475857
Postoperative hypertension	10.10	10.02	3	112232	35	110477029
Device computer issue	10.09	10.02	4	112231	116	110476948
Blood creatinine increased	10.08	10.02	250	111985	182639	110294425
Right ventricular failure	10.07	10.02	7	112228	25947	110451117
Red blood cell sedimentation rate increased	10.07	10.02	43	112192	78259	110398805
Product preparation error	10.05	10.02	29	112206	10850	110466214
Streptococcal infection	10.03	10.02	29	112206	10861	110466203

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C02AC01	CARDIOVASCULAR SYSTEM ANTIHYPERTENSIVES ANTIADRENERGIC AGENTS, CENTRALLY ACTING Imidazoline receptor agonists
ATC	C02LC01	CARDIOVASCULAR SYSTEM ANTIHYPERTENSIVES ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION Imidazoline receptor agonists in combination with diuretics
ATC	C02LC51	CARDIOVASCULAR SYSTEM ANTIHYPERTENSIVES ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION Imidazoline receptor agonists in combination with diuretics
ATC	N02CX02	NERVOUS SYSTEM ANALGESICS ANTIMIGRAINE PREPARATIONS Other antimigraine preparations
ATC	S01EA04	SENSORY ORGANS OPHTHALMOLOGICALS ANTIGLAUCOMA PREPARATIONS AND MIOTICS Sympathomimetics in glaucoma therapy
FDA MoA	N0000009918	Adrenergic alpha2-Agonists
FDA EPC	N0000175554	Central alpha-2 Adrenergic Agonist
MeSH PA	D000316	Adrenergic alpha-Agonists
MeSH PA	D000700	Analgesics
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D013565	Sympatholytics
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D018689	Sensory System Agents
MeSH PA	D058647	Adrenergic alpha-2 Receptor Agonists
CHEBI has role	CHEBI:35481	non-narcotic analgesic
CHEBI has role	CHEBI:35569	α-adrenergic agonist
CHEBI has role	CHEBI:35674	antihypertensive agent
CHEBI has role	CHEBI:66991	sympatholytic agent

Related Drugs by ATC class:

C02AC Imidazoline receptor agonists 4 drugs

guanfacinemoxonidinerilmenidinetolonidine

C02LC Imidazoline receptor agonists in combination with diuretics 1 drug

moxonidine

N02CX Other antimigraine preparations 4 drugs

dimetotiazineiprazochromeoxetoronepizotifen

S01EA Sympathomimetics in glaucoma therapy 5 drugs

apraclonidinebrimonidinedipivefrineepinephrineripasudil

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypertensive disorder	indication	38341003	DOID:10763
Severe pain	indication	76948002
Open-angle glaucoma	indication	84494001	DOID:1067
Attention deficit hyperactivity disorder	indication	406506008
Increased Intraocular Pressure after Ocular Procedure	indication
Ocular hypertension	off-label use	4210003	DOID:9282
Gilles de la Tourette's syndrome	off-label use	5158005	DOID:11119
Pain	off-label use	22253000
Diarrhea	off-label use	62315008
Opioid withdrawal	off-label use	87132004
Menopausal flushing	off-label use	198436008
Smoking cessation assistance	off-label use	384742004
Nicotine Withdrawal Symptoms	off-label use
Anuria	contraindication	2472002	DOID:2983
Hypercholesterolemia	contraindication	13644009
Myocardial infarction	contraindication	22298006	DOID:5844
Depressive disorder	contraindication	35489007
Hyperuricemia	contraindication	35885006	DOID:1920
Hypokalemia	contraindication	43339004
Diabetes mellitus type 2	contraindication	44054006	DOID:9352
Conduction disorder of the heart	contraindication	44808001
Low blood pressure	contraindication	45007003
Tear film insufficiency	contraindication	46152009
End stage renal disease	contraindication	46177005	DOID:784
Diabetes mellitus type 1	contraindication	46635009	DOID:9744
Bradycardia	contraindication	48867003
Sinus bradycardia	contraindication	49710005
Systemic lupus erythematosus	contraindication	55464009	DOID:9074
Sympathectomy	contraindication	57071006
Acute nephropathy	contraindication	58574008
Hepatic failure	contraindication	59927004
Cerebrovascular disease	contraindication	62914000	DOID:6713
Blood coagulation disorder	contraindication	64779008	DOID:1247
Hypercalcemia	contraindication	66931009	DOID:12678
Hypochloremic alkalosis	contraindication	70134007
Decreased respiratory function	contraindication	80954004
Oliguria	contraindication	83128009
Hyponatremia	contraindication	89627008
Gout	contraindication	90560007	DOID:13189
Magnetic resonance imaging	contraindication	113091000
Perioperative care	contraindication	133897009
Hypomagnesemia	contraindication	190855004
Acute pancreatitis	contraindication	197456007	DOID:2913
Atrioventricular block	contraindication	233917008	DOID:0050820
Labor pain	contraindication	247412007
Raynaud's phenomenon	contraindication	266261006
Syncope	contraindication	271594007
Surgical procedure	contraindication	387713003
Chronic myocardial ischemia	contraindication	413844008	DOID:3393
Myocardial ischemia	contraindication	414795007	DOID:3393
Inflammatory dermatosis	contraindication	703938007
Vagal Reflex Bradycardia	contraindication
Severe Cardiopulmonary Disease	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.5	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
0.1MG/ML	ONYDA XR	TRIS PHARMA INC	N217645	May 24, 2024	RX	SUSPENSION, EXTENDED RELEASE	ORAL	11918689	July 28, 2041	METHOD FOR DELIVERING AN EFFECTIVE AMOUNT OF CLONIDINE FOR A 24-HOUR PERIOD USING A SINGLE ORAL CLONIDINE COMPOSITION ACCORDING TO CLAIM 1 PRIOR TO BED TIME
0.1MG/ML	ONYDA XR	TRIS PHARMA INC	N217645	May 24, 2024	RX	SUSPENSION, EXTENDED RELEASE	ORAL	12576032	July 28, 2041	METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN	AGONIST	Ki	8.42		CHEMBL	CHEMBL
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN	AGONIST	Ki	7.50		CHEMBL	CHEMBL
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN	AGONIST	EC50	6.70		WOMBAT-PK	CHEMBL
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	5.16		CHEMBL
5-hydroxytryptamine receptor 7	GPCR	P34969	5HT7R_HUMAN		Ki	6.06		CHEMBL
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN		Ki	6.50		PDSP
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	6.22		CHEMBL
Alpha-1B adrenergic receptor	GPCR	P35368	ADA1B_HUMAN		Ki	6.50		PDSP
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	4.65		CHEMBL
Solute carrier family 22 member 2	Transporter	O15244	S22A2_HUMAN		IC50	4.80		WOMBAT-PK
Multidrug and toxin extrusion protein 1	Transporter	Q96FL8	S47A1_HUMAN		IC50	4.48		CHEMBL
Transmembrane protein 97	Enzyme	Q5BJF2	TMM97_HUMAN		Ki	5.56		CHEMBL
Nischarin	Membrane receptor	Q9Y2I1	NISCH_HUMAN		Ki	8.05		CHEMBL
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	5.49		CHEMBL
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	5.04		CHEMBL
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	5.99		DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		Kd	6.59		CHEMBL
Alpha-2B adrenergic receptor	GPCR		ADA2B_RAT		Ki	8.08		CHEMBL
Alpha-1D adrenergic receptor	GPCR		ADA1D_RAT	AGONIST	Ki	6.90		IUPHAR
5-hydroxytryptamine receptor 1A	GPCR		5HT1A_RAT		IC50	5.27		CHEMBL
Alpha-2A adrenergic receptor	GPCR		ADA2A_RAT		Ki	9.41		CHEMBL
Alpha-1A adrenergic receptor	GPCR		ADA1A_BOVIN		EC50	7.05		CHEMBL
Alpha-2A adrenergic receptor	GPCR		ADA2A_BOVIN		IC50	8.70		CHEMBL
Beta-1 adrenergic receptor	GPCR		B0FL73_CAVPO		Kd	4.40		CHEMBL
Nischarin	Membrane receptor		NISCH_RAT		Ki	6.95		CHEMBL
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1	Ion channel		HCN1_MOUSE	BLOCKER	IC50	4.40		IUPHAR
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2	Ion channel		HCN2_MOUSE	BLOCKER	IC50	5.10		IUPHAR
Adrenergic receptor alpha-2	GPCR		ADA2B_RAT ADA2C_RAT ADA2A_RAT		Ki	8.82		CHEMBL
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4	Ion channel		HCN4_MOUSE	BLOCKER	IC50	5		IUPHAR
Alpha-1B adrenergic receptor	GPCR		G3HDX1_CRIGR		EC50	7.08		CHEMBL

External reference:

ID	Source
4017850	VUID
N0000146207	NUI
D00281	KEGG_DRUG
4205-91-8	SECONDARY_CAS_RN
142432	RXNORM
C0009014	UMLSCUI
CHEBI:46631	CHEBI
CLU	PDB_CHEM_ID
CHEMBL134	ChEMBL_ID
DB00575	DRUGBANK_ID
CHEMBL1705	ChEMBL_ID
D003000	MESH_DESCRIPTOR_UI
2803	PUBCHEM_CID
516	IUPHAR_LIGAND_ID
2624	INN_ID
MN3L5RMN02	UNII
27687	MMSL
372108	MMSL
381	MMSL
4478	MMSL
4479	MMSL
89106	MMSL
d00044	MMSL
000644	NDDF
004495	NDDF
372805007	SNOMEDCT_US
387121001	SNOMEDCT_US
62782004	SNOMEDCT_US
4017849	VANDF
4017850	VANDF
MN3L5RMN02	INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Clonidine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9723	INJECTION, SOLUTION	500 ug	INTRAVENOUS	ANDA	21 sections
Clonidine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9724	INJECTION, SOLUTION	100 ug	INTRAVENOUS	ANDA	21 sections
Clonidine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0228-2127	TABLET	0.10 mg	ORAL	ANDA	11 sections
Clonidine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0228-2128	TABLET	0.20 mg	ORAL	ANDA	11 sections
Clonidine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0228-2129	TABLET	0.30 mg	ORAL	ANDA	11 sections
Clonidine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0228-4241	TABLET, EXTENDED RELEASE	0.10 mg	ORAL	ANDA	19 sections
Clonidine	HUMAN PRESCRIPTION DRUG LABEL	1	0378-0871	PATCH	0.10 mg	TRANSDERMAL	ANDA	17 sections
Clonidine	HUMAN PRESCRIPTION DRUG LABEL	1	0378-0872	PATCH	0.20 mg	TRANSDERMAL	ANDA	17 sections
Clonidine	HUMAN PRESCRIPTION DRUG LABEL	1	0378-0873	PATCH	0.30 mg	TRANSDERMAL	ANDA	17 sections
Clonidine transdermal system	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3508	PATCH	0.10 mg	TRANSDERMAL	ANDA	21 sections
Clonidine transdermal system	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3509	PATCH	0.20 mg	TRANSDERMAL	ANDA	21 sections
Clonidine transdermal system	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3510	PATCH	0.30 mg	TRANSDERMAL	ANDA	21 sections
Clonidine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0615-2572	TABLET	0.10 mg	ORAL	ANDA	11 sections
Clonidine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0615-2574	TABLET	0.30 mg	ORAL	ANDA	11 sections
Clonidine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8272	TABLET	0.20 mg	ORAL	ANDA	11 sections
Clonidine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7442	TABLET	0.10 mg	ORAL	ANDA	23 sections
Clonidine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7443	TABLET	0.20 mg	ORAL	ANDA	23 sections
CLONIDINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	10135-708	TABLET	0.10 mg	ORAL	ANDA	20 sections
CLONIDINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	10135-709	TABLET	0.20 mg	ORAL	ANDA	20 sections
CLONIDINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	10135-710	TABLET	0.30 mg	ORAL	ANDA	20 sections
Clonidine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10544-042	TABLET	0.30 mg	ORAL	ANDA	20 sections
CLONIDINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	10544-158	TABLET	0.20 mg	ORAL	ANDA	21 sections
Clonidine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10544-196	TABLET	0.10 mg	ORAL	ANDA	24 sections
Clonidine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10544-199	TABLET	0.20 mg	ORAL	ANDA	24 sections
Clonidine HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	12634-465	TABLET	0.10 mg	ORAL	ANDA	14 sections
CLONIDINE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-266	TABLET	0.10 mg	ORAL	ANDA	10 sections
CLONIDINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-267	TABLET	0.20 mg	ORAL	ANDA	11 sections
CLONIDINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	21695-371	TABLET	0.10 mg	ORAL	ANDA	21 sections
CLONIDINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	21695-372	TABLET	0.20 mg	ORAL	ANDA	21 sections
CLONIDINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	21695-377	TABLET	0.30 mg	ORAL	ANDA	21 sections